The DOI matches its Crossref record; 288 of the 288 references it cites were found in a registry or an index.
The ErbB/HER family of protein-tyrosine kinases and cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Brand, T. M., Iida, M., Luthar, N., Wleklinski, M. J., Starr, M. M., & Wheeler, D. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071518 · Cited by 30
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains
Hanks, S. K., Quinn, A. M., & Hunter, T. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,039
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,289
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Weinberg, R. A., & Weinberg, R. A. (2006) · W.W. Norton eBooks · doi:10.1201/9780203852569 · Cited by 1,751
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 1×
“This dimer nterface results in the burial of ≈2020 Å2 of surface area [64].”
BackgroundERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationThe SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., Ullrich, A., Skolnik, E. Y., Bar-Sagi, D., & Schlessinger, J. (1992) · Cell · doi:10.1016/0092-8674(92)90167-b · Cited by 1,631
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Gillen, S., Schuster, T., Meyer zum Büschenfelde, C., Friess, H., & Kleeff, J. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000267 · Cited by 1,552
Domchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Requirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Carpenter, G., & Cohen, S. (1976) · The Journal of cell biology · doi:10.1083/jcb.71.1.159 · Cited by 1,286
Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
Nolen, B., Taylor, S., & Ghosh, G. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.024 · Cited by 1,167
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995) · Nature · doi:10.1038/378390a0 · Cited by 1,148
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
Miettinen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z., & Derynck, R. (1995) · Nature · doi:10.1038/376337a0 · Cited by 1,039
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor
Schlessinger, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00966-2 · Cited by 993
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
Protein kinases: evolution of dynamic regulatory proteins
Taylor, S. S., & Kornev, A. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.006 · Cited by 945
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn442 · Cited by 939
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
The influence of lipophilicity in drug discovery and design
Arnott, J. A., & Planey, S. L. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.714363 · Cited by 868
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J., & Lemmon, M. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00047-9 · Cited by 801
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.
Cohen, S., Ushiro, H., Stoscheck, C., & Chinkers, M. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68224-4 · Cited by 776
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Severe neuropathies in mice with targeted mutations in the ErbB3 receptor
Riethmacher, D., Sonnenberg-Riethmacher, E., Brinkmann, V., Yamaai, T., Lewin, G. R., & Birchmeier, C. (1997) · Nature · doi:10.1038/39593 · Cited by 729
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 719
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas
Smit, V. T. H. B. M., Boot, A. J. M., Smits, A. M. M., Fleuren, G. J., Cornelisse, C. J., & Bos, J. L. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.16.7773 · Cited by 626
Meanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
Kadamur, G., & Ross, E. M. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183750 · Cited by 610
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 606
Wooster, R., & Weber, B. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012284 · Cited by 605
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Self-citationSrc protein–tyrosine kinase structure and regulation
Roskoski, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.171 · Cited by 596
Self-citationThe deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Protein kinase C, an elusive therapeutic target?
Mochly-Rosen, D., Das, K., & Grimes, K. V. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3871 · Cited by 563
Emerging roles of pseudokinases
Boudeau, J., Miranda-Saavedra, D., Barton, G. J., & Alessi, D. R. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.07.003 · Cited by 547
Antibody Therapeutics in Cancer
Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543
Lung cancer: diagnosis and management.
Collins, L. G., Haines, C., Perkel, R. L., & Enck, R. E. (2007) · PubMed · Cited by 541
Spatial control of EGF receptor activation by reversible dimerization on living cells
Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010) · Nature · doi:10.1038/nature08827 · Cited by 538
ADAM17: a molecular switch to control inflammation and tissue regeneration
Scheller, J., Chalaris, A., Garbers, C., & Rose-John, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.005 · Cited by 526
The Structure of the Nuclear Pore Complex
Hoelz, A., Debler, E. W., & Blobel, G. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060109-151030 · Cited by 523
Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0912 · Cited by 505
Architecture and Membrane Interactions of the EGF Receptor
Arkhipov, A., Shan, Y., Das, R., Endres, N. F., Eastwood, M. P., Wemmer, D. E., Kuriyan, J., & Shaw, D. E. (2013) · Cell · doi:10.1016/j.cell.2012.12.030 · Cited by 504
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
Guidelines for Human Gene Nomenclature
Wain, H. M., Bruford, E. A., Lovering, R. C., Lush, M. J., Wright, M. W., & Povey, S. (2002) · Genomics · doi:10.1006/geno.2002.6748 · Cited by 500
Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor
Endres, N. F., Das, R., Smith, A. W., Arkhipov, A., Kovacs, E., Huang, Y., Pelton, J. G., Shan, Y., Shaw, D. E., Wemmer, D. E., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.032 · Cited by 490
Mechanism of biological synergy between cellular Src and epidermal growth factor receptor
Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1415 · Cited by 472
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
Hatanpaa, K. J., Burma, S., Zhao, D., & Habib, A. A. (2010) · Neoplasia · doi:10.1593/neo.10688 · Cited by 471
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., & Quintás-Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 418
Chaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1468 · Cited by 418
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Longva, K. E., Blystad, F. D., Stang, E., Larsen, A. M., Johannessen, L. E., & Madshus, I. H. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200106056 · Cited by 386
Cook, P. F., Neville, M. E., Vrana, K. E., Hartl, F. T., & Roskoski, R. (1982) · Biochemistry · doi:10.1021/bi00266a011 · Cited by 379
Self-citationRAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationRexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
The nuclear envelope environment and its cancer connections
Chow, K.-H., Factor, R. E., & Ullman, K. S. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3219 · Cited by 359
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Sardi, S. P., Murtie, J., Koirala, S., Patten, B. A., & Corfas, G. (2006) · Cell · doi:10.1016/j.cell.2006.07.037 · Cited by 349
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor
Roskoski, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.150 · Cited by 345
Self-citationThe initial clinical trial of nitrogen mustard
Gilman, A. (1963) · The American Journal of Surgery · doi:10.1016/0002-9610(63)90232-0 · Cited by 338
Steroid-hormone receptors in breast cancer
Wittliff, J. L. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3+<630::aid-cncr2820531308>3.0.co;2-3 · Cited by 325
The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Red Brewer, M., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 317
Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Soria, J.-C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., Burcoveanu, D., Fukuoka, M., Besse, B., & Pignon, J.-P. (2013) · Annals of Oncology · doi:10.1093/annonc/mds590 · Cited by 314
Nuclear EGFR contributes to acquired resistance to cetuximab
Li, C., Iida, M., Dunn, E. F., Ghia, A. J., & Wheeler, D. L. (2009) · Oncogene · doi:10.1038/onc.2009.234 · Cited by 313
The role of ubiquitylation in receptor endocytosis and endosomal sorting
Haglund, K., & Dikic, I. (2012) · Journal of Cell Science · doi:10.1242/jcs.091280 · Cited by 313
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
He, K., Iyer, K. R., Hayes, R. N., Sinz, M., Woolf, T. F., & Hollenberg, P. F. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970192k · Cited by 312
v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas.
Langdon, W. Y., Hartley, J. W., Klinken, S. P., Ruscetti, S. K., & Morse, H. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1168 · Cited by 307
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Self-citationEstrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer
Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1061 · Cited by 293
Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2134 · Cited by 293
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
Küppers, R., Engert, A., & Hansmann, M.-L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61245 · Cited by 286
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Wilson, K. J., Gilmore, J. L., Foley, J., Lemmon, M. A., & Riese, D. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.008 · Cited by 285
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 284
Fan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
MEK1/2 dual-specificity protein kinases: Structure and regulation
Roskoski, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 276
Self-citationNucleocytoplasmic shuttling of signal transducers
Xu, L., & Massagué, J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1331 · Cited by 272
Endocytosis of growth factor receptors
Sorkin, A., & Waters, C. M. (1993) · BioEssays · doi:10.1002/bies.950150603 · Cited by 272
De Grève, J., Teugels, E., Geers, C., Decoster, L., Galdermans, D., De Mey, J., Everaert, H., Umelo, I., Veld, P. I., & Schallier, D. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.008 · Cited by 271
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., & Cataldo, D. (2008) · Biochimie · doi:10.1016/j.biochi.2007.08.008 · Cited by 266
Rewcastle, G. W., Denny, W. A., Bridges, A. J., Zhou, H., Cody, D. R., McMichael, A., & Fry, D. W. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a008 · Cited by 263
Epidermal growth factor receptor tyrosine kinase
Ward, W. H. J., Cook, P. N., Slater, A. M., Davies, D. H., Holdgate, G. A., & Green, L. R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90042-6 · Cited by 261
Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family
Hsu, S.-C., & Hung, M.-C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610014200 · Cited by 260
Mechanism of action of trastuzumab and scientific update
BASELGA, J. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90276-3 · Cited by 258
Ueda, S., Ogata, S., Tsuda, H., Kawarabayashi, N., Kimura, M., Sugiura, Y., Tamai, S., Matsubara, O., Hatsuse, K., & Mochizuki, H. (2004) · Pancreas · doi:10.1097/00006676-200407000-00061 · Cited by 245
Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor
Giri, D. K., Ali-Seyed, M., Li, L.-Y., Lee, D.-F., Ling, P., Bartholomeusz, G., Wang, S.-C., & Hung, M.-C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11005-11018.2005 · Cited by 244
The Neuregulin-I/ErbB Signaling System in Development and Disease
(2007) · Advances in Anatomy Embryology and Cell Biology · doi:10.1007/978-3-540-37107-6 · Cited by 243
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 240
Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1
Lo, H., Ali‐Seyed, M., Wu, Y., Bartholomeusz, G., Hsu, S., & Hung, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20876 · Cited by 240
Lu, C., Mi, L.-Z., Grey, M. J., Zhu, J., Graef, E., Yokoyama, S., & Springer, T. A. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00742-10 · Cited by 234
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins
Wang, Y.-N., Yamaguchi, H., Hsu, J.-M., & Hung, M.-C. (2010) · Oncogene · doi:10.1038/onc.2010.157 · Cited by 233
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Taylor, S. S., Keshwani, M. M., Steichen, J. M., & Kornev, A. P. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0054 · Cited by 233
Brosig, B., & Langosch, D. (1998) · Protein Science · doi:10.1002/pro.5560070423 · Cited by 229
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., González-Angulo, A. M., Mills, G. B., Penuel, E., Winslow, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1872 · Cited by 228
Nucleocytoplasmic transport: Ran, beta and beyond
Kuersten, S., Ohno, M., & Mattaj, I. W. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02144-4 · Cited by 228
HER2 Mutation and Response to Trastuzumab Therapy in Non–Small-Cell Lung Cancer
Cappuzzo, F., Bemis, L., & Varella-Garcia, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmc060020 · Cited by 216
A Novel Juxtamembrane Domain Isoform of HER4/ErbB4
Elenius, K., Corfas, G., Paul, S., Choi, C. J., Rio, C., Plowman, G. D., & Klagsbrun, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26761 · Cited by 214
FDA Drug Approval Summary: Panitumumab (Vectibix™)
Giusti, R. M., Shastri, K. A., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-577 · Cited by 214
Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A., Frezza, A. M., Venditti, O., Imperatori, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr623 · Cited by 211
Cited by
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., et al. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.001 · Cited by 1,486
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 79
- Pages
- 34-74
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2070727232
- Cited by
- 1,353
- References
- 288
- FWCI
- 36.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.